Life Clinical Trials — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$1,519,628	7
2024	Research	$548,996	29
2023	Research	$111,922	7
2022	Research	$81,393	49
2021	Research	$85,382	5

Breakdown

Who paid Research payments · program years 2021–2025

Amgen Inc. $1,994,057 13 payments
E.R. Squibb & Sons, L.L.C. $272,353 9 payments
Incyte Corporation $53,915 12 payments
Vertex Pharmaceuticals Incorporated $11,000 1 payment
Verrica Pharmaceuticals Inc. $8,750 1 payment
Sun Pharmaceutical Industries Inc. $7,244 61 payments

Studies the money was for Research payments · program years 2021–2025

A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants $1,413,938 1 payment
P4 Uncontrolled Gout FORWARD II $419,408 1 payment
Phase III Study -SLE #2 - A Phase 3, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2) $159,543 2 payments
Ph2b In Subjects with SLE $66,672 2 payments
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) $53,915 12 payments
P2b SLE $47,799 3 payments
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) $38,280 1 payment
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis $26,000 1 payment
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis $23,340 1 payment
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Na ve to Biologic Disease-modifying Anti-rheumatic Drugs $22,827 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.